Pharmaceutical Manufacturing and Packaging of Erythromycin Base 250 mg Tablets

The contract seeks the manufacture, quality control, packaging, and preservation of 1,000 bottles of Erythromycin Base 250 mg Tablets adhering to both military and FDA standards. The work must be performed in compliance with stringent regulatory requirements to ensure product safety, potency, and consistency, with all processes documented and verified to meet defense and pharmaceutical industry protocols. Packaging must be suitable for military logistics and storage conditions, preserving the integrity of the tablets throughout the supply chain until deployment. The opportunity is issued as a subcontract under the NAICS code 325412 for Pharmaceutical Preparation Manufacturing, with the Department of Defense through its Medical Supply Chain Pharm FSA as the contracting entity. The place of performance is designated as Dyess AFB, Texas, with a response deadline of July 20, 2026, and the solicitation was posted on July 13, 2026. All bidders must be prepared to demonstrate their capacity to handle regulated pharmaceutical production under federal oversight, with complete traceability and adherence to quality assurance systems mandated by the military and FDA.